Marchioli Roberto, Levantesi Giacomo
Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud Chieti, Italy.
Front Physiol. 2012 Jun 28;3:202. doi: 10.3389/fphys.2012.00202. eCollection 2012.
After the first reports about a protective effect on coronary heart disease (CHD) published more than 40 years ago, wide interest in the therapeutic use of n-3 polyunsaturated fatty acids (n-3 PUFA) aroused. Since then, many studies and meta-analyses have reported a significantly reduced risk of CHD and CV death due to fish and n-3 PUFA intake. Some of the overviews reported a significant reduction of risk of sudden cardiac death, all-cause death, and nonfatal CV events. On the other side, recent clinical trials had mixed findings, raising concern about the consistency of the evidence on n-3 PUFA. We critically reviewed recent large clinical trials reporting data on the antiarrhythmic effects of n-3 PUFA in different clinical settings, i.e., patients with CHD, heart failure, with implantable cardioverter defibrillator, and at risk of atrial fibrillation, in order to summarize the results which are available up to date and possibly give "substantiated" fuel to the debate on the conflicting results of n-3 PUFA.
在40多年前首次报道了对冠心病（CHD）有保护作用之后，人们对n-3多不饱和脂肪酸（n-3 PUFA）的治疗用途产生了广泛兴趣。从那时起，许多研究和荟萃分析报告称，由于摄入鱼类和n-3 PUFA，冠心病和心血管死亡风险显著降低。一些综述报告称，心脏性猝死、全因死亡和非致命性心血管事件的风险显著降低。另一方面，最近的临床试验结果不一，这引发了人们对n-3 PUFA证据一致性的担忧。我们批判性地回顾了最近的大型临床试验，这些试验报告了n-3 PUFA在不同临床环境中的抗心律失常作用的数据，即冠心病患者、心力衰竭患者、植入式心脏复律除颤器患者以及有房颤风险的患者，以便总结目前可得的结果，并可能为关于n-3 PUFA相互矛盾结果的争论提供“有根据的”依据。
